2009-10-27 21:16:03 -

ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the Oppenheimer 20 th Annual Healthcare Conference on Tuesday, November 3, 2009 at 4:30 p.m. eastern time. ArQule’s presentation will be web cast live and can be accessed through the investor relations section of the Company’s website, www.arqule.com : .

The conference will be held at the Waldorf-Astoria Hotel, New York.


About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead product, which is in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase.

Additional clinical-stage programs include compounds that inhibit the Eg5 kinesin spindle protein and compounds that activate the cell’s DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company’s most advanced pre-clinical development program is focused on inhibition of the BRAF kinase. ArQule’s discovery efforts are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate).



ArQule, Inc. www.ArQule.com : William

B. Boni, 781-994-0300VP, Investor Relations/Corp.
Communications